在线国产一区二区_成人黄色片在线观看_国产成人免费_日韩精品免费在线视频_亚洲精品美女久久_欧美一级免费在线观看

US EUROPE AFRICA ASIA 中文
Business / Companies

Biotech boom, pride of Anhui

By Zhu Lixin (China Daily) Updated: 2016-07-19 08:14

Biotech boom, pride of Anhui

A bird's-eye view of the world's largest biotech drug production base in Hefei, Anhui province. The facility is shaped in the form of antibody ATCG. [Photo provided to China Daily]

Beijing-based Sinobioway Group Co Ltd, a major biotech company in China, is building the world's largest biotech drug production base at the Bantang township in Hefei, capital of Anhui province in East China.

The facility, shaped in the form of antibody ATCG and to be called the Bantang Bioeconomy Experimental Zone, will have 100 production lines to be completed in 10 to 15 years. The first five lines will be completed by the end of this year.

Work on another 10 will also start later this year, said Cao Wenbo, president of Anhui Sinobioway Bioeconomy Group, a subsidiary of Sinobioway Group.

The zone covers an area of 31 sq km. A 400,000-sq-meter plant is almost ready; the next two phases will take up 600,000 sq m.

Cao said infrastructure excluding the production lines will see an investment of 1.5 billion yuan ($224.3 million), which is being provided by the Hefei government.

Wu Cunrong, Party chief of Hefei city, said: "We believe the biotech drug sector will see enormous growth opportunities in future, so we will surely support such companies."

The company, Cao said, will repay the money in five years "so that we can have more money for mergers and acquisitions. We have enough money to reach the goal."

There are dozens of funds to back the ambitious project, which is expected to cost billions of yuan, he said.

"Instead of starting from the R&D stage, Sinobioway is more interested in buying drug patents and firms at home and abroad. Biotech drug production has been very profitable. But starting everything from R&D will be too time-consuming and risky. You may spend years but get nothing."

He said buying patents and firms will bring the company high profits quickly. During the process, it will also develop its own drugs.

This business model has marked the collaboration between Sinobioway and BioAlta, a San Diego-based company focused on the development of Conditionally Active Biologic antibody therapeutics.

In 2015, the two companies forged a strategic collaboration for the development and commercialization of select CAB antibodies and other CAB-based therapeutics in China. "Production of all the drugs will be based in Hefei," said Cao.

BioAlta would receive more than $70 million in payments and investment from Sinobioway in a year, according to their agreement.

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 成人三级在线 | 精品网站999www| 国产精品久久久久久久久借妻 | 成人欧美日韩 | av黄页| 精品日韩在线观看 | 亚洲天堂男人天堂 | 操操av| 久久99深爱久久99精品 | 日韩欧美在线视频观看 | 亚洲69视频| av不卡在线播放 | 黄色网免费 | 精品欧美一区二区三区久久久 | 国产精品av在线 | 国产精品美女久久 | 日韩在线视频网站 | 亚洲一区二区三区四区在线 | 欧美精产国品一二三区 | 91av免费在线观看 | 日韩视频在线免费观看 | 99热视| 日韩欧美激情 | 狠狠婷婷| 国产一区二区视频在线 | a在线视频| av免费观看网站 | 亚洲视频一区在线观看 | 中文字幕一二三四区 | 深夜福利网 | 超碰在线99 | 日本毛片视频 | 在线一区视频 | 中文字幕不卡视频 | 国产精品亚洲综合 | 99热在线免费观看 | 成人一区二区视频 | 国产精品一区二 | 国产精品亚洲精品 | 一区二区黄色 | 午夜丁香|